F182112+P
Phase 2Small molecule
F182112+P is one of 23 small molecule programs targeting Multiple Myeloma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1135 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Ninlaro
TakedaPreclinical
Prolia
AmgenPreclinical
Eliquis
Bristol-Myers SquibbPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Nolvadex
AstraZenecaPreclinical
Oncovin
EEastern Cooperative Oncology Group
Preclinical
Intron a
Merck & Co.Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
F182112+P
SShandong New Time Pharmaceutical Co., LTD
Phase 2
Abecma
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for F182112+P. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details